Authors
Minori Takamura, Kentaro Tamura, Risa Sugito, Naoko Takahashi, Shiko Honma, Masahiro Yoshida, Hiroshi Wakui, Hitomi Sekiguchi, Ryusuke Kizawa, Susumu Saito, Sachi Matsubayashi, Ayu Kiritani, Keitaro Okuda, Hirofumi Utsumi, Saburo Ito, Shunsuke Minagawa, Takanori Numata, Hiromichi Hara, Jun Araya
Published in
JTO clinical and research reports. Volume 7. Issue 10. Pages 101052. Epub Jul 14, 2026.
Abstract
There is no established treatment for relapsed SCLC in patients with interstitial lung disease. We report the case of a 67-year-old man with idiopathic pulmonary fibrosis (IPF) receiving nintedanib who developed a postoperative relapse of SCLC. After cisplatin plus etoposide therapy, the patient developed an acute exacerbation of IPF, which improved with corticosteroid therapy. However, pleural dissemination and pulmonary metastases progressed, leading to the initiation of tarlatamab. During follow-up, transient ground-glass opacities appeared around pulmonary metastases. These opacities resolved, and tumor shrinkage was observed. The patient achieved a partial response without new toxicities, and the therapy was ongoing. Immunohistochemical analysis using an anti-delta-like ligand 3 antibody (SP347) reported strong expression in tumor cells but no detectable expression in adjacent normal or fibrotic lung tissue. This finding provides a possible biological rationale. This case suggests that tarlatamab may be a potential therapeutic option in selected patients with relapsed SCLC complicated by IPF.
PMID:
42733924
Bibliographic data and abstract were imported from PubMed on 14 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0